A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue sarcomas

BACKGROUND: Ontuxizumab, a humanized monoclonal antibody, targets endosialin (tumor endothelial marker 1 [TEM‐1] or CD248), which is expressed on sarcoma cells and is believed to be involved in tumor angiogenesis. This is the first trial to evaluate ontuxizumab in patients with sarcoma. METHODS: Par...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Robin L., Chawla, Sant P., Attia, Steven, Schöffski, Patrick, Gelderblom, Hans, Chmielowski, Bartosz, Le Cesne, Axel, Van Tine, Brian A., Trent, Jonathan C., Patel, Shreyaskumar, Wagner, Andrew J., Chugh, Rashmi, Heyburn, John W., Weil, Susan C., Wang, Wenquan, Viele, Kert, Maki, Robert G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618088/
https://www.ncbi.nlm.nih.gov/pubmed/31034598
http://dx.doi.org/10.1002/cncr.32084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618088/
https://www.ncbi.nlm.nih.gov/pubmed/31034598
http://dx.doi.org/10.1002/cncr.32084

Ejemplares similares